OTTAWA —
Over the next month Canada will be experiencing a “temporary” delay in Pfizer-BioNTech vaccine shipments due to the pharmaceutical giant’s expansion plans at its European manufacturing facility, with the shortage resulting in an average of 50 per cent of coming doses delayed each week.
While shipments will continue in the coming weeks, the amount of doses in them will be lessened, sometimes by hundreds of thousands of doses.
“Pfizer has confirmed that Canada’s deliveries will be impacted for the next four weeks. We will see an average reduction over this timeframe of 50 per cent of expected deliveries. There will minimal impact next week… The most profound impact will be in the week of January 25,” said Maj.-Gen. Dany Fortin, who is leading Canada’s logistical rollout.
This setback to Canada’s short-term COVID-19 vaccine delivery schedule means the number of doses going to each province and territory will have to be readjusted. Fortin said that the allocations will begin to scale back up in the first two weeks of February, before returning to the size of doses originally anticipated.
Canada was planning on receiving between 124,800 and 366,600 Pfizer doses every week between now and the end of February, as part of the plan to have six million doses total from Pfizer and Moderna by the end of March when Phase 1 ends.
The delivery for the week of Jan. 25, which Fortin said is likely to see the largest reduction, was set to be 208,650 doses. If that’s reduced by half, Canada will receive 104,325 Pfizer doses that week, which is fewer than the forecasted allocation received this week.
“In my conversation this morning with Pfizer, it was very clear that we’re are still correct in our planning assumption to receive approximately four million doses of Pfizer by March 31,” Fortin said,
Fortin said that knew the company would at some point need to scale-up their manufacturing to ramp-up its mass production, but the news of the looming construction project was brought to the federal government’s attention in the last 24 hours, according to Treasury Board President Jean-Yves Duclos.
Procurement Minister Anita Anand announced the delay on Friday, saying all nations who are receiving vaccines from this Pfizer facility will be receiving fewer doses.
“It is a temporary reduction, it’s not a stoppage… We will make up those doses,” Anand said.
Addressing the setback during his Rideau Cottage address on Friday, Prime Minister Justin Trudeau said that shipments have largely been ahead of schedule so far, but that “with an undertaking this historic, it’s only to be expected that there will be a few bumps along the way.”
Norway, which is also receiving Pfizer doses from its Europe facilities has announced that “for some time ahead” their deliveries will be reduced. In the coming week their shipment will be reduced by approximately 18 per cent.
“The reduction is due to a reorganisation at Pfizer in connection with an upgrade of production capacity… It is not yet clear how long it will take before Pfizer is up to maximum production capacity again,” said the statement published by the Norwegian Institute of Public Health.
The government sought to ensure that all countries who will be impacted, will be “equitably treated” in terms of delivery reductions, according to Anand. Fortin confirmed later Friday that this will be the case, with all seeing deliveries reduced by 50 per cent on average.
Anand said that while Canada is expecting to be able to catch up, the delay is “unfortunate.”
“However such delays and issues are to be expected when global supply chains are stretched well beyond their limits,” Anand said.
By end of the day Friday, the federal government will have distributed a total of 929,000 doses of the two approved COVID-19 vaccines, around 84 per cent of which have been administered.
WON’T IMPACT PHASE 2
The plan is to receive “more than” one million doses of approved vaccines every week, on average, starting in April with Phase 2.
Trudeau said that while this issue is out of Canada’s hands, the country “must still get ready for the ramp-up,” in Phase 2.
Fortin said the delays “will not change our second quarter goals,” though he could not guarantee future delays. He said he understands and feels the “disappointment,” but “we need to move forward.”
He committed to keep all key stakeholders, and Canadians appraised of any future delivery schedule changes.
The ongoing initial vaccination stage has seen Canada pushing to properly allocate and prioritize key groups like residents and staff in long-term care homes as well as front-line health-care workers.
In this first stage of the vaccine campaign, Canada has seen both doses sitting in freezers as well as provinces saying they are running short, while those on the front line have sought to sort out who should and shouldn’t be receiving shots at this time.
“It was with precisely these types of issues in mind that Canada pursued the aggressive procurement strategy that we did,” Anand said. “This approach of ensuring diversity and volume months ago is what now gives us flexibility and margins to remain on track in difficult times.”
Asked whether Canada will be looking to revisit their decision to not procure additional Moderna doses to make up the shortage over the next few weeks, Fortin said the amount scheduled to arrive from that company will stay the same.
As previously reported, the additional 16 million Moderna doses that the federal government left on the table in talks with that company would not be arriving until late 2021.
As for whether Canada looked into being able to receive Pfizer shipments from the United States facility, Fortin said that the federal government looked into it, but for now Canada’s line of doses will continue to come exclusively from the European facility.
Health Minister Patty Hajdu added that because as part of the regulatory approval granted to Pfizer, Health Canada approves the manufacturing sites as well as the vaccine itself.
“So, should we procure from even the same company a different site, then there would need to be review of the manufacturing data,” she said.
Several federal officials sought to reassure Canadians Friday that the country remains on track to vaccinate everyone who wants to be, by the end of September.
TORONTO – Roots Corp. may have built its brand on all things comfy and cosy, but its CEO says activewear is now “really becoming a core part” of the brand.
The category, which at Roots spans leggings, tracksuits, sports bras and bike shorts, has seen such sustained double-digit growth that Meghan Roach plans to make it a key part of the business’ future.
“It’s an area … you will see us continue to expand upon,” she told analysts on a Friday call.
The Toronto-based retailer’s push into activewear has taken shape over many years and included several turns as the official designer and supplier of Team Canada’s Olympic uniform.
But consumers have had plenty of choice when it comes to workout gear and other apparel suited to their sporting needs. On top of the slew of athletic brands like Nike and Adidas, shoppers have also gravitated toward Lululemon Athletica Inc., Alo and Vuori, ramping up competition in the activewear category.
Roach feels Roots’ toehold in the category stems from the fit, feel and following its merchandise has cultivated.
“Our product really resonates with (shoppers) because you can wear it through multiple different use cases and occasions,” she said.
“We’ve been seeing customers come back again and again for some of these core products in our activewear collection.”
Her remarks came the same day as Roots revealed it lost $5.2 million in its latest quarter compared with a loss of $5.3 million in the same quarter last year.
The company said the second-quarter loss amounted to 13 cents per diluted share for the quarter ended Aug. 3, the same as a year earlier.
In presenting the results, Roach reminded analysts that the first half of the year is usually “seasonally small,” representing just 30 per cent of the company’s annual sales.
Sales for the second quarter totalled $47.7 million, down from $49.4 million in the same quarter last year.
The move lower came as direct-to-consumer sales amounted to $36.4 million, down from $37.1 million a year earlier, as comparable sales edged down 0.2 per cent.
The numbers reflect the fact that Roots continued to grapple with inventory challenges in the company’s Cooper fleece line that first cropped up in its previous quarter.
Roots recently began to use artificial intelligence to assist with daily inventory replenishments and said more tools helping with allocation will go live in the next quarter.
Beyond that time period, the company intends to keep exploring AI and renovate more of its stores.
It will also re-evaluate its design ranks.
Roots announced Friday that chief product officer Karuna Scheinfeld has stepped down.
Rather than fill the role, the company plans to hire senior level design talent with international experience in the outdoor and activewear sectors who will take on tasks previously done by the chief product officer.
This report by The Canadian Press was first published Sept. 13, 2024.
VANCOUVER – Mediated talks between the union representing HandyDART workers in Metro Vancouver and its employer, Transdev, are set to resume today as a strike that has stopped most services drags into a second week.
No timeline has been set for the length of the negotiations, but Joe McCann, president of the Amalgamated Transit Union Local 1724, says they are willing to stay there as long as it takes, even if talks drag on all night.
About 600 employees of the door-to-door transit service for people unable to navigate the conventional transit system have been on strike since last Tuesday, pausing service for all but essential medical trips.
Hundreds of drivers rallied outside TransLink’s head office earlier this week, calling for the transportation provider to intervene in the dispute with Transdev, which was contracted to oversee HandyDART service.
Transdev said earlier this week that it will provide a reply to the union’s latest proposal on Thursday.
A statement from the company said it “strongly believes” that their employees deserve fair wages, and that a fair contract “must balance the needs of their employees, clients and taxpayers.”
This report by The Canadian Press was first published Sept. 12, 2024.
MONTREAL – Travel company Transat AT Inc. reported a loss in its latest quarter compared with a profit a year earlier as its revenue edged lower.
The parent company of Air Transat says it lost $39.9 million or $1.03 per diluted share in its quarter ended July 31.
The result compared with a profit of $57.3 million or $1.49 per diluted share a year earlier.
Revenue in what was the company’s third quarter totalled $736.2 million, down from $746.3 million in the same quarter last year.
On an adjusted basis, Transat says it lost $1.10 per share in its latest quarter compared with an adjusted profit of $1.10 per share a year earlier.
Transat chief executive Annick Guérard says demand for leisure travel remains healthy, as evidenced by higher traffic, but consumers are increasingly price conscious given the current economic uncertainty.
This report by The Canadian Press was first published Sept. 12, 2024.
